WO2014134832A1 - 组合物及其制备方法 - Google Patents
组合物及其制备方法 Download PDFInfo
- Publication number
- WO2014134832A1 WO2014134832A1 PCT/CN2013/072370 CN2013072370W WO2014134832A1 WO 2014134832 A1 WO2014134832 A1 WO 2014134832A1 CN 2013072370 W CN2013072370 W CN 2013072370W WO 2014134832 A1 WO2014134832 A1 WO 2014134832A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- hawthorn
- weight
- extract
- oats
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 238000002360 preparation method Methods 0.000 title claims description 42
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 44
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 44
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 44
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 44
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 44
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 44
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 44
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 44
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 44
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 44
- 235000007319 Avena orientalis Nutrition 0.000 claims description 53
- 244000075850 Avena orientalis Species 0.000 claims description 53
- 241001092040 Crataegus Species 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000000284 extract Substances 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 28
- 239000008280 blood Substances 0.000 claims description 28
- 239000012071 phase Substances 0.000 claims description 25
- 239000007901 soft capsule Substances 0.000 claims description 23
- 239000006071 cream Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 235000013402 health food Nutrition 0.000 claims description 19
- 239000008346 aqueous phase Substances 0.000 claims description 18
- 235000020717 hawthorn extract Nutrition 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 239000002674 ointment Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 241001300674 Plukenetia volubilis Species 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 12
- 208000003351 Melanosis Diseases 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000004166 Lanolin Substances 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 235000019388 lanolin Nutrition 0.000 claims description 8
- 229940039717 lanolin Drugs 0.000 claims description 8
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 235000019271 petrolatum Nutrition 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 claims description 4
- 229940075529 glyceryl stearate Drugs 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 239000003871 white petrolatum Substances 0.000 claims description 4
- 239000004382 Amylase Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 235000007106 Crataegus suborbiculata Nutrition 0.000 claims description 2
- 241000073432 Crataegus suborbiculata Species 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 235000013202 a hawthorn Nutrition 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 206010014970 Ephelides Diseases 0.000 claims 1
- 102000011759 adducin Human genes 0.000 claims 1
- 108010076723 adducin Proteins 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 abstract description 47
- 241000976924 Inca Species 0.000 abstract description 43
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 38
- 239000003921 oil Substances 0.000 description 35
- 235000019198 oils Nutrition 0.000 description 35
- 230000000694 effects Effects 0.000 description 22
- 230000037396 body weight Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 238000010298 pulverizing process Methods 0.000 description 13
- 210000000577 adipose tissue Anatomy 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 230000003796 beauty Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 206010008570 Chloasma Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 208000016261 weight loss Diseases 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000004820 blood count Methods 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000004003 subcutaneous fat Anatomy 0.000 description 5
- 235000007558 Avena sp Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229910021487 silica fume Inorganic materials 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 210000000852 deltoid muscle Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 235000014571 nuts Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000008278 cosmetic cream Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002036 drum drying Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001113 umbilicus Anatomy 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 230000007371 visceral function Effects 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000004005 Nypa fruticans Species 0.000 description 1
- 235000005305 Nypa fruticans Nutrition 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012899 de-mixing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Definitions
- the present invention relates to the field of health foods and cosmetics, and in particular to a composition comprising Inca fruit, and to a method of preparing the composition. Background technique
- BMI body mass index
- WHO World Health Organization
- Weight loss refers to the reduction of excess fat in the state of human health, thereby reducing body weight, reducing body fat content, and controlling body composition at an appropriate level.
- the commonly used methods of weight loss include diet adjustment, medical control, exercise plus diet control.
- Common diet control and increased exercise are currently advocated for weight loss health methods, but they also have disadvantages such as difficulty in persisting and easy rebound, and commonly used medical methods.
- Liposuction, western medicine control, etc. have fatal shortcomings such as patient suffering and toxic side effects.
- the Chinese SFDA has stopped the production and sales of the slimming drug sibutramine on October 30, 2010.
- the US FDA and the European Union have also stopped using it for weight loss. The reason is that sibutramine causes heart and brain.
- the present invention is directed to solving at least some of the above technical problems or at least providing a useful commercial choice. Accordingly, it is an object of the present invention to provide a composition comprising Inca fruit and having the effect of slimming and skin care, which can be prepared into a functional food, health food or cosmetic product for beauty loss. . All the raw materials in the product are derived from nature, safe and effective, and the sources of raw materials are wide, the composition is reasonable, the curative effect is exact, the preparation process is simple, the storage and transportation are safe, and the production cost is low.
- the invention provides a composition comprising: 10-120 parts by weight of Inca; 50-240 parts by weight of hawthorn; and 40-300, according to an embodiment of the invention Parts by weight of oatmeal.
- a composition comprising a mixture of Inca, and hawthorn and oatmeal has obvious synergistic effects and technological advancement characteristics
- the present invention The composition described is effective in slimming and skin care, and the effect of the composition is significantly better than that of the single component, and has a remarkable synergistic effect.
- the composition preferably comprises: 30-90 parts by weight of Inca; 80-200 parts by weight of hawthorn; and 60-250 parts by weight of oats.
- the composition most preferably comprises: 50 parts by weight of Inca; 180 parts by weight of hawthorn; and 150 parts by weight of oats.
- the effect of the composition for slimming and skin care can be further improved.
- Inca fruit is the genus Oleaceae, also known as Inca peanut, South American vine, Star vine, Meito fruit.
- the perennial oil plant native to the Amazonian rainforest of South America, was originally transformed from the Incas to the wild, and has been used by local indigenous people for thousands of years in the Inca region of South America. When planted in the same year, the fruit can be hung.
- the seeds are rich in oil, protein, amino acids, vitamin A, vitamin E and some other trace elements.
- Inca oil contains extremely rich unsaturated fatty acids ( ⁇ -3, ⁇ -6, ⁇ - 9), as well as vitamins, strontium and protein, and the content of three unsaturated fatty acids is over 92%.
- Inca fruit oil is rich in anti-oxidant phenols, and the content of ⁇ and ⁇ tocopherol exceeds 2000 mg / kg. Such high content of tocopherol makes its taste and quality very stable during storage.
- Inca fruits and oils rich in polyunsaturated fatty acids are safe to eat, and can be eaten directly after salad or frying.
- Hawthorn is cultivated all over the country. It is a homologous plant of medicine and food. It has the same acidity, sweetness and sweet taste. It is spleen, stomach and liver. It has digestion and stomach, diverts phlegm, turbidity and lipid-lowering. It is used for meat stagnation, stomach cramps, diarrhea, abdominal pain, blood stasis, postpartum stagnation, heart tingling, chest pain, suffocation, hyperlipidemia. In recent years, the clinical use of raw hawthorn has been used for the treatment of hypertension, coronary heart disease and hyperlipidemia.
- Oats are an important food and feed crop, which is a worldwide cultivated crop. It is the largest in Inner Mongolia (about 35% of the country's total area). Oatmeal has a high nutritional value, it is rich in protein, unsaturated fat Acids, vitamins and minerals, etc., the most striking of which is that oats are rich in soluble dietary fiber, the main component of which is ⁇ -glucan. Beta-glucan has special functions such as lowering cholesterol, lowering blood pressure, regulating blood sugar, changing the microbial composition of the intestinal system, preventing colon cancer, improving immunity, and beauty.
- the composition may be a functional food, a health food or a cosmetic. Therefore, it can be easily used.
- the form of the composition is not particularly limited.
- the composition is in the form of a capsule, a tablet, a granule, a pill, an ointment, a cream or a cream.
- the composition can be prepared into a health food, a cosmetic or the like.
- a health food a cosmetic or the like.
- capsules, tablets, granules, pills, ointments, creams, and creams can be prepared by a conventional process, together with auxiliaries commonly used in pharmacy.
- an ointment, a cream, and a cream can be prepared by a conventional process, together with an auxiliary agent commonly used in pharmacy.
- the invention provides a method of preparing the composition described above.
- the method comprises: mixing a predetermined ratio of enamel, hawthorn and oats to obtain the composition.
- the Inca fruit is provided in the form of Inca fruit oil obtained by cold-pressing, filtering, and removing the nuts of the Inca fruit.
- the hawthorn is provided in the form of hawthorn ethanol extract.
- the oatmeal is provided in the form of an oat extract, wherein the oat extract is obtained by the following steps: after pulverizing the oat, using 10 times the amount of water at 60 ° C, pH 9.0 After extracting for 1.5 h, the ⁇ -amylase was used at a concentration of 25 U/ml, and the starch in the reaction solution was hydrolyzed at 80 ° C and pH 7.0 for 30 min, then vigorously stirred, and hydrochloric acid was added to adjust the pH of the extract to 5.0.
- the oat extract is obtained by the following steps: after pulverizing the oat, using 10 times the amount of water at 60 ° C, pH 9.0 After extracting for 1.5 h, the ⁇ -amylase was used at a concentration of 25 U/ml, and the starch in the reaction solution was hydrolyzed at 80 ° C and pH 7.0 for 30 min, then vigorously stirred, and hydrochloric acid was added to adjust the pH of the extract to 5.0.
- the upper layer deproteinized aqueous phase was obtained, 95% ethanol was slowly added to the aqueous phase, the alcohol concentration was adjusted to 50%, and the mixture was allowed to stand overnight, and the precipitate was lyophilized to obtain the oat extract.
- the preparation method may include: mixing Inca, Hawthorn, and oats, and pulverizing the obtained mixture to a particle size of 10 to 150 ⁇ m to obtain a mixed fine powder; and obtaining the obtained The mixed fine powder is made into a solid preparation to obtain the composition.
- the preparation method may include: mixing hawthorn, oatmeal, and pulverizing to a particle size of 60 ⁇ m to obtain a mixed fine powder; mixing the mixed fine powder with the imprinted fruit oil, The resulting mixture is made into a soft capsule to obtain a composition in the form of a capsule.
- the preparation method may include: mixing stearic acid, lanolin, glycerin, inca nut, hawthorn extract and heating and melting at 50 ° C to obtain an oil phase; Dissolved in distilled water, added to the oat extract, heated at 50 ° C to obtain an aqueous phase; and the aqueous phase was mixed with the oil phase and stirred to obtain a composition in the form of a cream.
- the preparation method may include: melting petrolatum, lanolin, liquid paraffin at 50 ° C, cooling to 40 ° C; adding inca fruit oil, hawthorn powder, oat flour and nipa Gold ethyl ester is stirred and used to obtain a composition in the form of an ointment.
- the preparation method may include: heating glyceryl stearate, stearic acid, white petrolatum, liquid paraffin at 50 ° C to melt to obtain an oil phase; Sodium sulfate, glycerin, triethanolamine and water are slowly dissolved by heating at 50 ° C to obtain an aqueous phase; the oil phase is mixed with the aqueous phase, and oat extract and hawthorn extract are added to the obtained mixture and Ingredients are stirred and allowed to obtain a composition in the form of a cream.
- the Inca fruit of the present invention may be obtained by harvesting the fruit of the Inca fruit, first peeling the fruit, drying it, and obtaining the Indo fruit (nut).
- the ingrown fruit oil of the present invention is obtained by adding cold-squeezing, filtering and de-mixing the nuts of the Inca fruit to the printing and adding the fruit oil.
- the hawthorn extract of the present invention may be obtained by crushing hawthorn and passing through a No. 1 sieve (the No. 1 sieve in the Chinese Pharmacopoeia is 10 mesh), and using 6 times the amount of 70%. The ethanol was refluxed and extracted three times, each time for 1 hour, and dried under reduced pressure to obtain a hawthorn extract.
- the oat extract of the present invention may be obtained by pulverizing oats, passing through a No. 2 sieve (the No. 1 sieve in the Chinese Pharmacopoeia is 24 mesh), and using 10 times the amount of water 60°. C, pH 9.0 extraction for 1.5h, using ct-amylase, concentration of 25U / ml extract, 80 ° C, pH 7.0 conditions for 30min hydrolysis of the starch in the reaction solution, then vigorously stirred, add hydrochloric acid to adjust extraction The pH of the solution was 5.0, and the solution was allowed to stand and centrifuged to obtain an upper deproteinized aqueous phase. 95% ethanol was slowly added to the aqueous phase to adjust the alcohol concentration to 50%, and the mixture was allowed to stand overnight, and the precipitate was lyophilized to obtain an oat extract.
- a No. 2 sieve the No. 1 sieve in the Chinese Pharmacopoeia is 24 mesh
- concentration of 25U / ml extract 80 °
- the solid preparation of the composition product of the present invention is prepared as follows: Ingredients are mixed with hawthorn (or hawthorn extract), oatmeal (or oat extract), and processed by ultrafine pulverizing equipment. The fine powder of the pulverized Inca fruit powder, the hawthorn extract powder, and the oat extract powder having a particle diameter of 10 to 150 ⁇ m is pulverized. The auxiliary materials commonly used in pharmacy are added, and the desired solid preparation product dosage forms such as capsules, tablets, granules, granules and the like are prepared according to the existing production techniques.
- the soft capsule preparation method of the composition product of the present invention is as follows: Weigh the hawthorn and oats, and pulverize into a mixed fine powder having a particle diameter of 60 ⁇ m by using an ultrafine pulverizing apparatus, and use it as a spare; After printing at low temperature, add the fruit oil, put the ingrown fruit oil in the batching tank, stir at a constant speed, add the fine powder obtained by the pulverization, stir for 30 minutes, mix the liquid and the liquid, grind and grind three times, and grind after grinding. The vacuum is depleted of air bubbles, and the content material liquid is prepared.
- the content material liquid is placed in a soft capsule pilling machine, filled into soft capsules, and then dried into a drum drying device to dry and soften the soft capsules, and then sterilized and scrubbed by ethanol. Pills, by controlling the ambient temperature and humidity (less than 50%) of the drying chamber, the capsule shell moisture and ethanol are naturally evaporated, the drying time is not less than 20 hours, until the surface of the capsule is dry and smooth, slightly elastic, and the drying is completed. Finally, the unqualified soft capsules such as the appearance and the joints are sorted and discarded, and the qualified ones will be qualified.
- the soft capsules are packaged in the form of a bottle or a blister sheet, that is, a soft capsule is obtained.
- the cream preparation of the composition product of the present invention is as follows: Stearic acid, lanolin, glycerin, ino fruit oil, hawthorn extract are placed in a container, and heated and melted at 50 ° C to obtain an oil phase. Another triethanolamine is dissolved in distilled water, added oat extract, heated at 50 ° C, the aqueous phase is obtained, the temperature is lowered to 40 ° C, the aqueous phase is slowly added to the oil phase, and continuously stirred in the same direction to a brownish yellow fine paste. That is, a cream is obtained.
- the ointment preparation method of the composition product of the present invention is as follows: Weigh Vaseline, lanolin, liquid paraffin at 50 ° C, cool down to 40 ° C, slowly add Inca fruit oil, and hawthorn powder , oat flour, add a small amount of ethylparaben and stir evenly to obtain an ointment.
- the cream preparation method of the composition product of the present invention is as follows: Weigh glyceryl stearate, stearic acid, white petrolatum, liquid paraffin, slowly heated to melt at 50 ° C, and at 50 ° C is insulated to make the oil phase. In addition, sodium lauryl sulfate, glycerin, triethanolamine and water are weighed. Slowly heat and dissolve at 50 °C to make the aqueous phase. When the temperature rises to the same as the oil phase, the oil phase is slowly added to the water. In the middle, and constantly stirring. The oat extract is dissolved in an appropriate amount of distilled water, and the hawthorn extract and the oat extract and the inca fruit are added to the two-phase mixture, and the mixture is cooled to obtain a cream.
- the Ingredients and oils of the present invention are directly edible, and the hawthorn is a homologous plant of medicines and medicines. Oatmeal is an important food and feed crop, so the composition of the present invention is Safe and non-toxic.
- the composition of the present invention can significantly reduce body weight, blood sugar level, and serum total cholesterol in a nutritionally obese rat.
- the composition of the present invention has a significant weight loss effect on the human body, and has a beautiful skin care effect on the human body to eliminate chloasma, and has no side effects on the human body.
- the composition of the present invention also has a health-care effect of lowering blood sugar, lowering blood fat, resisting oxidation and delaying aging.
- the invention provides the use of the above composition of the invention in the preparation of a formulation.
- the composition may be prepared in any convenient dosage form, for example, as a capsule, tablet, granule, pill, ointment, cream or cream.
- the above preparation having the composition can be used for at least one of blood sugar lowering, blood fat lowering, beauty ecchymosis, and treatment of obesity.
- the composition is supplied to the human body in the form of a preparation, thereby exerting effects of lowering blood sugar, lowering blood fat, cosmetic freckle, and treating obesity.
- All the raw materials in the composition of the invention are natural, natural and safe, and the raw materials are widely available.
- the compatibility of the prescriptions is scientific and reasonable, the curative effect is exact, the preparation process is simple, the storage and transportation are safe, and the production is safe. low cost.
- the invention combines the substance and function of the indo-fruit, hawthorn and oatmeal, and can promote digestion and increase the diet. Dietary fiber, increase satiety, lower blood sugar, lower lipid-lowering, and improve skin condition, whitening, and freckle by conditioning body functions, and promote synergy between slimming and skin care.
- each raw material is processed and pulverized by ultra-fine pulverizing equipment, so that the raw materials of the indo-fruit, hawthorn and oat raw materials are micronized, which is favorable for the uniform dispersion of the active ingredients in the raw materials, and is more favorable for human body absorption.
- the composition of the invention has obvious efficacy, good safety and stable quality, and the product can be preserved for a long time, which provides a new choice for daily health care.
- the preparation process is as follows:
- the preparation process is as follows:
- Preparation method Weigh 80g of Inca fruit, 180g of hawthorn, 150g of oatmeal, and pulverize it with ultrafine pulverizing equipment to obtain mixed fine powder with particle size of 80 microns, adding starch, microcrystalline cellulose, micro-silica gel, according to existing Hard capsule production technology filling.
- the preparation process is as follows:
- the preparation process is as follows:
- hawthorn extract and oat extract are prepared same as that in the first embodiment
- the preparation process is as follows:
- the preparation process is as follows:
- hawthorn extract and oat extract are prepared same as that in the first embodiment
- Example 9 Effects on body weight, blood glucose and blood lipids in nutritional obese rats
- the health food soft capsule used in the present embodiment is prepared by the method of Example 4, and has a specification of 1.0 g/granule.
- the recommended food method is 2 times a day, 2 capsules each time.
- Experimental animals 45 Wistar rats, born about 1 month, weighing about 150g, male and female, good health, provided by the Experimental Animal Center of Wuhan University Medical College, production license number: SCXK (E) 2008-0004.
- Rats were randomly divided into three groups, namely, the normal servo group (A), the high energy servo group (B), and the high energy servo intervention group (C).
- the B and C groups were fed with high energy feeding for 8 weeks, and the group C was used.
- Soft capsule intervention the dose was 25mg/kg body weight, divided into two doses for 30d.
- the obese animal model is equipped with 100 g of feed, 10% casein, 38.63 % lard, 39.63 % starch, 3.5% mixed inorganic salt, 1.0% mixed vitamin, 8.0% soybean oil, 30g / 100 g body weight.
- Rats were fed for 8 weeks. Animals of each group were weighed once every two days and recorded in detail. Eight weeks after the A group and the B group were fed, the arterial blood was centrifuged at 1 500 r/min for 5 min, and plasma was collected to measure blood glucose and blood lipid levels.
- the weight of the health food soft capsule of the present invention is shown in Table 1.
- the weight of the high-energy feeding group is significantly higher than that of the conventional feeding group, and the high-energy feeding group feeding group B and C are fed for 8 weeks.
- the average body weight is [318.56 ⁇ 10.31g],
- the comparison of the weight, blood lipid and blood glucose of the health food soft capsule of the present invention is shown in Table 2.
- the rats were added with Inca fruit oats and hawthorn soft capsule for 30 days, body weight, serum total cholesterol and blood sugar level.
- the high-energy feeding group there was no significant difference compared with the conventional feeding group (P ⁇ 0.05); serum very low-density lipoprotein was higher than the high-energy feeding group, but no compared with the conventional feeding group.
- Significant difference P ⁇ 0.05).
- Table 1 Comparison of body weight between normal feeding group and high energy feeding group ( ⁇ s) Group 0 weeks body weight (g) 2 weeks body weight (g) 4 weeks body weight (g) 6 weeks body weight (g) 8 weeks body weight (g)
- the health food tablet used in the present embodiment is prepared by the method of Example 1, and has a specification of 1.0 g/granule.
- the recommended eating method is 2 times a day, 2 tablets each time.
- Subjects 40 patients with simple obesity who were over 20% overweight and had normal visceral function after physical examination.
- the subjects took 6 capsules a day for 3 consecutive days for 30 days.
- the daily diet and exercise during the test were consistent with those before the test.
- the indicators were tested once at the beginning and end of the test.
- Observation indicators include:
- biochemical indicators blood lipids (triacylglycerol, total bile, alcohol, high density lipoprotein cholesterol), albumin, total protein, blood uric acid, blood sugar, alanine aminotransferase, creatinine, urea nitrogen, uric acid.
- Overweight (%) (measured weight - standard weight) / standard weight xl 00%
- the four measurement sites are: the outer side of the lower deltoid muscle The midpoint, the right scapula, the right umbilicus 3 cm, and the right anterior superior iliac spine.
- Test items before the test refer to the normal range of total cholesterol (mmol / L) 5.54 ⁇ 0.97 4.36 ⁇ 0.87 2.8-6.0 triglyceride (mmol / L) 1.55 ⁇ 0.94 0.84 ⁇ 0.54 0.23-1.74 high density lipoprotein 1.34 ⁇ 0.37 1.24 ⁇ 0.24 0.90-1.45
- the health food ointment used in this embodiment is prepared by the method of Example 9, and the specification is 10.Og/branch, and is recommended. The method is to apply the affected area twice a day.
- Subjects Female patients with age-matched test requirements, aged 35-49 years, with facial yellow-brown spots of varying sizes and shapes, 36 cases, no other diseases, normal visceral function.
- the area of chloasma in 36 subjects before and after the test was (2675.21 ⁇ 1645.30) mm 2 and (2321.89 ⁇ 1547.37) mm 2 respectively .
- PO.01; chloasity was (1.79 ⁇ 0.49).
- Wo B (1.51 ⁇ 0.37), statistically tested, P ⁇ 0.01 o
- the subjects continued to use the health food ointment for 30 days.
- the clinical indicators of the subjects remained normal before and after the test, and the area and chroma of the chloasma decreased.
- the invented health food ointment has an obvious effect of eliminating chloasma on the human body, and has no obvious damage to the body.
- the description of the terms "one embodiment”, “some embodiments”, “example”, “specific example”, or “some examples” and the like means a specific feature described in connection with the embodiment or example.
- a structure, material or feature is included in at least one embodiment or example of the invention.
- the schematic representation of the above terms does not necessarily mean the same embodiment or example.
- the particular features, structures, materials, or characteristics described may be combined in a suitable manner in any one or more embodiments or examples.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380073947.9A CN105050611A (zh) | 2013-03-08 | 2013-03-08 | 组合物及其制备方法 |
PCT/CN2013/072370 WO2014134832A1 (zh) | 2013-03-08 | 2013-03-08 | 组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/072370 WO2014134832A1 (zh) | 2013-03-08 | 2013-03-08 | 组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014134832A1 true WO2014134832A1 (zh) | 2014-09-12 |
Family
ID=51490594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/072370 WO2014134832A1 (zh) | 2013-03-08 | 2013-03-08 | 组合物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN105050611A (zh) |
WO (1) | WO2014134832A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105021543A (zh) * | 2015-06-30 | 2015-11-04 | 广州金域医学检验中心有限公司 | 一种α-淀粉酶检测试剂及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1471848A (zh) * | 2003-07-08 | 2004-02-04 | 杜越新 | 以山楂粉、苦瓜粉为原料配制的用于调节血脂、血糖的食品 |
CN1864535A (zh) * | 2006-06-23 | 2006-11-22 | 中国农业大学 | 燕麦类降脂食品及加工方法 |
CN1883449A (zh) * | 2006-06-12 | 2006-12-27 | 乔爱娴 | 一种化妆品组合物及其制备方法 |
CN101484122A (zh) * | 2006-07-05 | 2009-07-15 | 科蒂·普雷斯蒂奇·兰嘉斯汀集团有限公司 | 包含具有抗老化作用的皮肤护理复合物的美容制品 |
CN101982163A (zh) * | 2010-10-27 | 2011-03-02 | 中国科学院西双版纳热带植物园 | 一种Omega-3脂肪酸油润肤霜及其制备方法 |
CN101999652A (zh) * | 2010-10-27 | 2011-04-06 | 中国科学院西双版纳热带植物园 | 一种具有降血脂功能的保健食品及其制备方法 |
CN102038876A (zh) * | 2009-10-15 | 2011-05-04 | 曹新社 | 一种高效减肥药 |
CN102266058A (zh) * | 2011-09-05 | 2011-12-07 | 张凤平 | 一种双山降脂营养片 |
-
2013
- 2013-03-08 WO PCT/CN2013/072370 patent/WO2014134832A1/zh active Application Filing
- 2013-03-08 CN CN201380073947.9A patent/CN105050611A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1471848A (zh) * | 2003-07-08 | 2004-02-04 | 杜越新 | 以山楂粉、苦瓜粉为原料配制的用于调节血脂、血糖的食品 |
CN1883449A (zh) * | 2006-06-12 | 2006-12-27 | 乔爱娴 | 一种化妆品组合物及其制备方法 |
CN1864535A (zh) * | 2006-06-23 | 2006-11-22 | 中国农业大学 | 燕麦类降脂食品及加工方法 |
CN101484122A (zh) * | 2006-07-05 | 2009-07-15 | 科蒂·普雷斯蒂奇·兰嘉斯汀集团有限公司 | 包含具有抗老化作用的皮肤护理复合物的美容制品 |
CN102038876A (zh) * | 2009-10-15 | 2011-05-04 | 曹新社 | 一种高效减肥药 |
CN101982163A (zh) * | 2010-10-27 | 2011-03-02 | 中国科学院西双版纳热带植物园 | 一种Omega-3脂肪酸油润肤霜及其制备方法 |
CN101999652A (zh) * | 2010-10-27 | 2011-04-06 | 中国科学院西双版纳热带植物园 | 一种具有降血脂功能的保健食品及其制备方法 |
CN102266058A (zh) * | 2011-09-05 | 2011-12-07 | 张凤平 | 一种双山降脂营养片 |
Non-Patent Citations (2)
Title |
---|
CAI, ZHIQUAN ET AL.: "Nutritional Evaluation in Seeds of a Woody Oil Crop Plukenetia volubilis Linneo", ACTA NUTRIMENTA SINICA, vol. 33, no. 2, December 2011 (2011-12-01), pages 193 - 195 * |
NATALIE, E.M. ET AL.: "Characterization and Authentication of a Novel Vegetable Source of Omega-3 Fatty Acids, Sacha Inchi (Plukenetia volubilis L.) oil", FOOD CHEMISTRY, vol. 134, March 2012 (2012-03-01), pages 1173 - 1180 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105021543A (zh) * | 2015-06-30 | 2015-11-04 | 广州金域医学检验中心有限公司 | 一种α-淀粉酶检测试剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105050611A (zh) | 2015-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101822749B (zh) | 治疗高血压高血脂的药物制剂及其制备方法 | |
CN101912110B (zh) | 一种具有减肥降糖降脂作用的组合物 | |
TWI426915B (zh) | 台灣藜用以製備治療高血脂症及高膽固醇症之藥物的用途及其醫藥組成物 | |
CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
CN107136281A (zh) | 一种用于改善女性肾功能的昆布虫草压片糖果及其制备方法 | |
CN105101817B (zh) | 可食用组合物及其制备方法和包含该组合物的食品 | |
CN105982905A (zh) | 20(R)-人参皂苷Rg3在制备预防或/和治疗肥胖症药物中的应用及药物 | |
CN108936632A (zh) | 一种磷虾油软胶囊及其制备方法 | |
CN103535625A (zh) | 一种调控血糖的食品及其制备方法 | |
CN1718016A (zh) | 一种微米糖参马桃花鹿补肾消疲豆奶片制备方法 | |
CN102389562A (zh) | 一种治疗小儿积滞的中药组合物 | |
WO2014134832A1 (zh) | 组合物及其制备方法 | |
CN102499366B (zh) | 调节血脂和抗疲劳的保健食品 | |
WO2016078088A1 (zh) | 美藤果油在调节动物肠道菌群中的用途 | |
WO2014134834A1 (zh) | 组合物以及包含其的食品、该食品的制备方法 | |
CN105995980A (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
CN108552525B (zh) | 一种降脂减肥功能食品 | |
CN106176510A (zh) | 一种用于美容保健的口服物及相应的美容保健组合物 | |
WO2021063016A1 (zh) | 一种具有降血脂功能的组合物及其制备方法和应用 | |
CN112335890A (zh) | 一种具有减重作用的组合使用的组合产品及其应用 | |
JP2007191478A (ja) | 苦瓜種子加工食品又は不妊等の改善食品若しくは改善薬とその製造方法 | |
CN110720527A (zh) | 一种中药减肥茶 | |
JP2007191478A5 (zh) | ||
CN110384782A (zh) | 一种干预痰湿体质的中药组合物、破壁组合物及其制备方法 | |
CN110037310A (zh) | 一种减肥胶囊及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201380073947.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13877295 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03.02.2016) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13877295 Country of ref document: EP Kind code of ref document: A1 |